AIN
Answer to Alzheimer' s

Answer to Alzheimer' s

location_on Virginia ,  United States

Please note:
Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. Investors are encouraged to review and evaluate the investments and determine at their own discretion, the appropriateness of making the particular investment. The information on this website is provided for informational purposes only, but we cannot guarantee that the information is accurate or complete. We strongly encourage investors to complete their own due diligence with licensed professionals, prior to making any investment and will not offer any legal or tax advice.

Short Summary

We are pioneering breakthrough therapies for Alzheimer’s with a novel approach that addresses the root causes rather than just symptoms. Our breakthrough technology is a paradigm shift in how Neurological diseases are treated.

Highlights

  • We have a cGMP Human Derived Manufactured Biologic
  • CEO is a Stanford Fellow with extensive background in Neuroscience
  • Our Advisory Board features internationally recognized leaders in neurology
  • Members of Johns Hopkins Tech Ventures in Baltimore
  • Success pre-seed funding of 200K

Overview

Target PKR 420,000,000
Minimum PKR 14,000,000
Investment Raised PKR 56,000,000
Previous Rounds PKR 56,000,000
Stage Pre-Startup/R&D
Investor Role Any

Ask a question
Got a question about this project?

Similar Projects